|
"yeh kh"的相關文件
顯示項目 16-25 / 103 (共11頁)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
每頁顯示[10|25|50]項目
| 國家衛生研究院 |
2018-01 |
Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma
|
Javle, M;Lowery, M;Shroff, RT;Weiss, KH;Springfeld, C;Borad, MJ;Ramanathan, RK;Goyal, L;Sadeghi, S;Macarulla, T;El-Khoueiry, A;Kelley, RK;Borbath, I;Choo, SP;Oh, DY;Philip, PA;Chen, LT;Reungwetwattana, T;Van Cutsem, E;Yeh, KH;Ciombor, K;Finn, RS;Patel, A;Sen, S;Porter, D;Isaacs, R;Zhu, AX;Abou-Alfa, GK;Bekaii-Saab, T |
| 國家衛生研究院 |
2017-12 |
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial
|
Kang, YK;Boku, N;Satoh, T;Ryu, MH;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, WK;Yeh, KH;Yoshikawa, T;Oh, SC;Bai, LY;Tamura, T;Lee, KW;Hamamoto, Y;Kim, JG;Chin, K;Oh, DY;Minashi, K;Cho, JY;Tsuda, M;Chen, LT |
| 國家衛生研究院 |
2017-11-16 |
Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer; A JSMO - ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS
|
Yoshino, T;Arnold, D;Taniguchi, H;Pentheroudakis, G;Yamazaki, K;Xu, RH;Kim, TW;Ismail, F;Tan, IB;Yeh, KH;Grothey, A;Zhang, S;Ahn, JB;Chong, D;Chen, LT;Kopetz, S;Eguchi-Nakajima, T;Ebi, H;Ohtsu, A;Cervantes, A;Muro, K;Tabernero, J;Minami, H;Ciardiello, F;Douillard, JY |
| 國家衛生研究院 |
2017-10 |
Anti-angiogenic therapy in patients with advanced gastric and gastroesophageal junction cancer: A systematic review
|
Chen, LT;Oh, DY;Ryu, MH;Yeh, KH;Yeo, W;Carlesi, R;Cheng, R;Kim, J;Orlando, M;Kang, YK |
| 國家衛生研究院 |
2017-10 |
First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma
|
Kuo, SH;Yeh, KH;Wu, MS;Lin, CW;Wei, MF;Liou, JM;Wang, HP;Chen, LT;Cheng, AL |
| 國家衛生研究院 |
2017-02 |
The B-cell-activating factor signalling pathway is associated with Helicobacter pylori independence in gastric mucosa-associated lymphoid tissue lymphoma without t(11;18)(q21;q21)
|
Kuo, SH;Tsai, HJ;Lin, CW;Yeh, KH;Lee, HW;Wei, MF;Shun, CT;Wu, MS;Hsu, PN;Chen, LT;Cheng, AL |
| 國家衛生研究院 |
2017-01 |
Expressions of the CagA protein and CagA-signaling molecules predict H. pylori-dependence of early-stage gastric DLBCL
|
Kuo, SH;Chen, LT;Lin, CW;Yeh, KH;Shun, CT;Tzeng, YS;Liou, JM;Wu, MS;Hsu, PN;Cheng, AL |
| 國家衛生研究院 |
2016-10 |
CagA and NFAT co-operatively participate in the lymphomagenesis of gastric MALT lymphoma
|
Kuo, SH;Tsai, HJ;Yeh, KH;Lin, CW;Zeng, YS;Wu, MS;Hsu, PN;Chen, LT;Cheng, AL |
| 國家衛生研究院 |
2016-05 |
Efficacy of frontline antibiotics therapy in the treatment of Helicobacter pylori-negative gastric low-grade mucosa-associated lymphoid tissue lymphoma
|
Kuo, SH;Yeh, KH;Wu, MS;Lin, CW;Tsai, HJ;Wei, MF;Lee, HW;Liou, JM;Chen, LT;Cheng, AL |
| 國家衛生研究院 |
2016-02 |
Results of Phase II trial of AUY922, a novel heat shock protein inhibitor in patients with metastatic gastrointestinal stromal tumor (GIST) and imatinib and sunitinib therapy
|
Chiang, NJ;Yeh, KH;Chiu, CF;Chen, JS;Yen, CC;Lee, KD;Lin, YL;Bai, LY;Chen, MH;Lin, JS;Yang, Y;Rau, KM;Hsiao, HH;Shan, YS;Chen, LT |
顯示項目 16-25 / 103 (共11頁)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
每頁顯示[10|25|50]項目
|
